News coverage about Otonomy (NASDAQ:OTIC) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Otonomy earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.1700096955756 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern Sentiment’s rankings:

Otonomy (NASDAQ OTIC) traded down $0.25 during trading hours on Monday, hitting $5.10. The company had a trading volume of 627,138 shares, compared to its average volume of 814,652. Otonomy has a fifty-two week low of $2.80 and a fifty-two week high of $21.15.

Otonomy (NASDAQ:OTIC) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.15. The business had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.43 million. Otonomy had a negative return on equity of 60.74% and a negative net margin of 7,899.03%. Otonomy’s revenue was down 12.8% on a year-over-year basis. analysts anticipate that Otonomy will post -2.88 EPS for the current year.

Several equities research analysts have issued reports on the company. ValuEngine downgraded Otonomy from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Piper Jaffray Companies restated a “hold” rating and issued a $8.00 price target on shares of Otonomy in a report on Friday, November 10th. J P Morgan Chase & Co downgraded Otonomy from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $28.00 to $8.00 in a report on Wednesday, August 30th. Zacks Investment Research upgraded Otonomy from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a report on Tuesday, November 14th. Finally, Cowen reiterated an “outperform” rating and set a $55.00 price objective on shares of Otonomy in a report on Wednesday, August 23rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $9.15.

COPYRIGHT VIOLATION WARNING: “Otonomy (OTIC) Given Daily Coverage Optimism Score of 0.07” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at

Otonomy Company Profile

Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.

Insider Buying and Selling by Quarter for Otonomy (NASDAQ:OTIC)

Receive News & Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.